Ralliant Corporation (NYSE:RAL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Ralliant Corporation (NYSE:RAL) have earned a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $69.00.

A number of analysts recently commented on the company. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Oppenheimer increased their price target on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Citigroup increased their price target on Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada increased their price target on Ralliant from $47.00 to $64.00 and gave the company a “sector perform” rating in a research report on Wednesday, May 13th. Finally, Truist Financial reissued a “buy” rating and set a $68.00 price objective (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th.

Hedge Funds Weigh In On Ralliant

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dodge & Cox grew its holdings in Ralliant by 13.3% during the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock valued at $621,849,000 after purchasing an additional 1,434,376 shares during the period. Viking Global Investors LP bought a new position in Ralliant during the second quarter valued at $257,200,000. Millennium Management LLC grew its holdings in Ralliant by 172.4% during the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after purchasing an additional 3,147,660 shares during the period. State Street Corp bought a new position in Ralliant during the second quarter valued at $213,096,000. Finally, Invesco Ltd. grew its holdings in Ralliant by 4.9% during the fourth quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock valued at $206,674,000 after purchasing an additional 187,898 shares during the period.

Ralliant Stock Performance

Shares of RAL opened at $72.26 on Tuesday. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $8.09 billion and a price-to-earnings ratio of -6.60. The stock has a 50 day moving average of $58.67 and a 200 day moving average of $51.40. Ralliant has a 12 month low of $37.27 and a 12 month high of $75.41.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The company had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, sell-side analysts forecast that Ralliant will post 2.64 earnings per share for the current year.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s dividend payout ratio is -1.83%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.